INTRODUCTION
Patients presenting with multiple thromboembolic events affecting diverse vascular beds are uncommon and management in the acute setting can be extremely difficult. Affected individuals are often younger, thrombotic events occur simultaneously or within days to weeks, and thrombosis frequently involves unusual sites [1] [2] [3] . Therapeutic management may be complicated by the concomitant presence of hemorrhagic risk factors (e.g., thrombocytopenia, DIC) or the need for surgical intervention. Kitchens first referred to this clinical presentation as "thrombotic storm" in 1998, identifying the following characteristic features: 1) an underlying hypercoagulable state is frequently present; 2) a provocative factor, or "trigger", is frequently associated with initiation of the thrombotic process; 3) new thromboembolic events develop rapidly, particularly if appropriate treatment is delayed; 4) prompt initiation of antithrombotic therapy is essential to achieve a successful outcome; and 5) long-term prognosis is good, if the cycle of thrombosis is interrupted early 1 . Other disorders. Catastrophic thrombotic events have been described in patients with idiopathic hypereosinophilic syndrome 56, 57 , Kimura disease 58 , inflammatory bowel disease 2, 59 , and
Behçet's disease 60,61 . Behçet's disease is associated with an increased risk for VTE, and, to a lesser extent, arterial occlusions and aneurysms 62 . The most common thrombotic complication in patients with Behçets disease is DVT, and patients frequently have recurrent events.
Different types of vascular involvement tend to cluster, such as dural sinus thrombosis and pulmonary artery thrombosis 63 . Anticoagulant therapy is the primary initial intervention in these patients. Homozygous deficiency of protein C or protein S is associated with neonatal purpura fulminans, which, in some cases, includes large vessel occlusions 64, 65 . Catastrophic venous thrombosis in a young adult with protein C deficiency has also been reported 66 . Management includes replacement of the deficient natural anticoagulant with fresh frozen plasma or protein C concentrates.
"Idiopathic" catastrophic thromboembolism. A subset of patients presenting with multiple thrombotic events will have none of the above disorders. Thrombotic complications include VTE, but these patients also sustain thrombotic events in unusual locations, including the 
DIAGNOSTIC APPROACH TO THE PATIENT PRESENTING WITH CATASTROPHIC THROMBOSIS
Initial diagnostic evaluation of a patient presenting with multifocal, or rapidly progressive, thrombotic events includes a thorough history and physical examination, relevant imaging studies, and clinical laboratory data ( Figure 1 ). The history needs to cover symptoms associated with the acute thrombotic event(s), including timing, location, pace of progression, response, if any, to initial (or ongoing) therapies, prior thrombotic events, and prior diagnosis of APS or aPL, or TTP. Potential precipitating events should be identified, including recent illnesses, procedures, minor trauma, and medication changes, including recent heparin exposure. For women of reproductive age, use of oral contraceptives or the possibility of pregnancy needs to be considered. For pregnant women, recent changes need to be reviewed (e.g., new hypertension, urinary protein levels). Prior personal or family history of thrombosis would suggest an inherited thrombophilia might be present. A thorough review of symptoms helps determine whether one needs to consider searching for an underlying malignancy or rheumatologic disorder.
The physical examination needs to assess the location and extent of thrombotic events, to guide decisions about imaging studies, determine the need for urgent intervention, and provide a baseline examination to assess response to therapy. Identification of lymphadenopathy, palpable masses or organomegaly, jaundice, or other unexpected findings should prompt evaluation for an underlying malignancy.
Imaging studies are needed to confirm the location, distribution, and overall burden of
thrombosis. An echocardiogram is useful for identifying cardiac valvular disease, intracardiac thrombosis, inter-atrial shunts in patients with arterial thromboembolism, and right heart compromise in patients with pulmonary embolism. Imaging for an occult malignancy is not recommended in the absence of clinical symptoms or findings.
The initial laboratory findings are important to confirm the diagnosis and guide management decisions ( Figure 1 ). Thrombocytopenia may be seen with any of these conditions, but the concomitant presence of schistocytes and an elevated LDH would favor a thrombotic microangiopathy. Catastrophic APS can also have laboratory evidence for a microangiopathic process, however, and, in the absence of a prior history of APS or SLE, a patient with catastrophic APS can appear very similar to a patient with TTP.
Isolated thrombocytopenia on presentation may be seen in patients with spontaneous (or delayed) HIT (Figure 1 ), but these patients may also present with a normal platelet count that drops rapidly with the initiation of heparin therapy. Coagulation studies are normal for some of these patients, but others present with or rapidly develop abnormal studies. A prolonged aPTT may signify the presence of a lupus anticoagulant, which is seen in >80% of patients with 
THERAPEUTIC MANAGEMENT OF PATIENTS PRESENTING WITH CATASTROPHIC THROMBOSIS
Given the lack of clinical trials defining the optimal therapeutic approach for patients with catastrophic thrombotic disorders, the following recommendations are empiric and based on review of available data and the authors' collective experiences. Prospective studies are needed, but the logistical difficulties of conducting such studies in these rare disorders are significant. for heparin, but it needs to be dose-adjusted in patients with renal insufficiency and can be more difficult to manage in the peri-procedural setting.
Rapidly achieving target therapeutic anticoagulant levels is critical in these patients. In certain situations, patients may require unusually high doses of intravenous heparin to achieve a therapeutic aPTT (e.g., >25 Units/kg/hour), a phenomenon referred to as "heparin Platelet counts need to be followed closely in patients on heparin or LMWH during pregnancy, since thrombocytopenia may develop for several reasons, and HIT during pregnancy, although rare, has been reported. Historically, danaparoid was used in these patients, but this agent is no longer available in the U.S. Argatroban 85 and fondaparinux 86 have been used in this clinical setting. We recommend that these patients be managed at Thrombosis Centers with expertise in Hematology and high-risk Maternal-Fetal Medicine.
Long-term management. We generally recommend that patients with catastrophic macrovascular thrombotic events be treated with indefinite anticoagulant therapy. Although a provoking event may have triggered the initial thrombotic event, the outcome is atypical and extreme, and we consequently favor treating these patients with a long-term antithrombotic strategy. 
Our patient's thrombotic diathesis continued to progress during DIC and did not improve when heparin therapy was re-initiated. Abnormal coagulation studies not only raised concerns

ACKNOWLEDGEMENTS
The authors wish to thank their colleagues in the Thrombotic Storm Study Group, the providers who have contacted us with questions and referrals of these complex patients, and the patients who have participated in research studies to better understand this disorder. The authors welcome any inquiries concerning patients with catastrophic thrombotic syndromes.
AUTHORSHIP
T.L.O., D.E., and C.S.K. all contributed to the writing and review of the manuscript.
CONFLICT OF INTEREST DISCLOSURE
The authors declare no conflicts of interest relevant to the topic or content of this manuscript. 
A r c h • Check anti-factor Xa level (confirm heparin present)
• Check factor VIII and fibrinogen levels (evaluate for acute phase response)
• Check antithrombin level (evaluate for acquired deficiency) and consider supplementation if low
• Continue to escalate UFH dose or consider an alternative anticoagulant (e.g., LMWH, argatroban, bivalirudin)
• Development of thrombocytopenia
• Re-check PT, fibrinogen, and D-dimer (evaluate for DIC)
• Re-evaluate blood film (evaluate for MAHA)
• Check anti-PF4/heparin immunoassay (evaluate for HIT)
• Consider changing from UFH to an alternative anticoagulant if HIT is strongly suspected
• New thrombotic event ("anticoagulant failure")
• Re-check aPTT, anti-factor Xa level (assess drug effect)
• Consider alternative treatment strategies (e.g., alternative
anticoagulant, thrombolytic therapy, initiation of plasma exchange or immunomodulatory therapy)
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